Biogen
Stock Forecast, Prediction & Price Target
Biogen (BIIB) stock Price Target by analysts
Biogen (BIIB) stock Price Target by analysts
Average Price Target
$247
Potential upside: 78.01%
Biogen price prediction
What is Biogen stock analysts` prediction?
Biogen stock forecast: Based on 8 Wall Street analysts` predicted price targets for Biogen in the last 3 months, the avarage price target is $247, with a high forecast of $NaN. The average price target represents a 78.01% change from the last price of $138.75.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Biogen stock Price Target by analysts
Full breakdown of analysts given Biogen price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Michael Yee Jefferies | 33.33% 1/3 | 10 months ago | $180 29.72% upside | $157.78 | StreetInsider | Previous targets (2) |
Brian Skorney Robert W. Baird | 33.33% 1/3 | 11 months ago | $300 116.21% upside | $162.83 | StreetInsider | Previous targets (2) |
Jay Olson Oppenheimer | 0% 0/2 | 11 months ago | $255 83.78% upside | $181.18 | StreetInsider | Previous targets (1) |
Terence Flynn Morgan Stanley | 0% 0/2 | 11 months ago | $204 47.02% upside | $181.18 | TheFly | Previous targets (1) |
Salveen Richter Goldman Sachs | 33.33% 1/3 | 11 months ago | $290 109.00% upside | $181.18 | StreetInsider | Previous targets (2) |
Christopher Raymond Raymond James | 0% 0/2 | 11 months ago | $315 127.02% upside | $181.18 | StreetInsider | Previous targets (1) |
Evan Seigerman BMO Capital | 50% 1/2 | 12 months ago | $230 65.76% upside | $188.17 | TheFly | Previous targets (1) |
Ashwani Verma UBS | 0% 0/1 | 12 months ago | $202 45.58% upside | $188.74 | TheFly | Previous targets (0) |
Laura Chico Wedbush | 75% 3/4 | about 1 year ago | $205 47.74% upside | $199.36 | TheFly | Previous targets (3) |
Brian Skorney Robert W. Baird | 33.33% 1/3 | about 1 year ago | $294 111.89% upside | $212.7 | StreetInsider | Previous targets (2) |
Brian Abrahams RBC Capital | 33.33% 1/3 | about 1 year ago | $282 103.24% upside | $214.16 | StreetInsider | Previous targets (2) |
Salveen Richter Goldman Sachs | 33.33% 1/3 | about 1 year ago | $342 146.48% upside | $211.17 | StreetInsider | Previous targets (2) |
Christopher Raymond Piper Sandler | 33.33% 1/3 | about 1 year ago | $307 121.26% upside | $211.17 | StreetInsider | Previous targets (2) |
Christopher Raymond Piper Sandler | 33.33% 1/3 | about 1 year ago | $313 125.58% upside | $236.8 | TheFly | Previous targets (2) |
Terence Flynn Morgan Stanley | 0% 0/2 | about 1 year ago | $311 124.14% upside | $232.75 | TheFly | Previous targets (1) |
George Farmer Scotiabank | 0% 0/1 | over 1 year ago | $275 98.19% upside | $230.28 | StreetInsider | Previous targets (0) |
Evan David Seigerman BMO Capital | 0% 0/2 | over 1 year ago | $260 87.38% upside | $220 | StreetInsider | Previous targets (1) |
Matthew Harrison Morgan Stanley | 33.33% 1/3 | over 1 year ago | $331 138.55% upside | $224.48 | StreetInsider | Previous targets (2) |
Christopher Raymond Raymond James | 0% 0/2 | over 1 year ago | $335 141.44% upside | $225.21 | StreetInsider | Previous targets (1) |
Paul Matteis Stifel Nicolaus | 0% 0/1 | over 1 year ago | $275 98.19% upside | $225.21 | StreetInsider | Previous targets (0) |
Laura Chico Wedbush | 75% 3/4 | over 1 year ago | $215 54.95% upside | $204.65 | TheFly | Previous targets (3) |
Brian Abrahams RBC Capital | 33.33% 1/3 | over 1 year ago | $317 128.46% upside | $201.99 | StreetInsider | Previous targets (2) |
Andrew Fein H.C. Wainwright | 0% 0/1 | over 1 year ago | $300 116.21% upside | $201.99 | StreetInsider | Previous targets (0) |
Jay Olson Oppenheimer | 0% 0/2 | over 1 year ago | $270 94.59% upside | $190.52 | StreetInsider | Previous targets (1) |
Carter Gould Barclays | 66.67% 2/3 | over 1 year ago | $215 54.95% upside | $206.38 | TheFly | Previous targets (2) |
Laura Chico Wedbush | 75% 3/4 | about 2 years ago | $269 93.87% upside | $271.23 | Benzinga | Previous targets (3) |
Yatin Suneja Guggenheim | 50% 1/2 | over 2 years ago | $350 152.25% upside | $311.11 | Benzinga | Previous targets (1) |
Unknown Atlantic Equities | N/A | almost 3 years ago | $295 112.61% upside | $305.17 | Benzinga | N/A |
Unknown Wedbush | N/A | almost 3 years ago | $247 78.01% upside | $302.84 | Benzinga | N/A |
Unknown Barclays | N/A | almost 3 years ago | $313 125.58% upside | $291.41 | Benzinga | N/A |
Unknown Jefferies | N/A | almost 3 years ago | $350 152.25% upside | $308.44 | Benzinga | N/A |
Unknown Truist Financial | N/A | almost 3 years ago | $350 152.25% upside | $301.86 | Benzinga | N/A |
Unknown Guggenheim | N/A | almost 3 years ago | $270 94.59% upside | $286.86 | Benzinga | N/A |
Unknown J.P. Morgan | N/A | almost 3 years ago | $275 98.19% upside | $264.28 | Benzinga | N/A |
Unknown Piper Sandler | N/A | about 3 years ago | $280 101.80% upside | $197.79 | Benzinga | N/A |
Unknown Wedbush | N/A | about 3 years ago | $217 56.39% upside | $277.58 | Benzinga | N/A |
Salim Syed Mizuho Securities | 100% 2/2 | about 3 years ago | $270 94.59% upside | $197.79 | StreetInsider | Previous targets (1) |
Steve Chesney Atlantic Equities | 50% 1/2 | about 3 years ago | $200 44.14% upside | $271.17 | Benzinga | Previous targets (1) |
Matthew Harrison Morgan Stanley | 33.33% 1/3 | about 3 years ago | $285 105.40% upside | $271.14 | Benzinga | Previous targets (2) |
Ami Fadia Needham | 25% 1/4 | about 3 years ago | $250 80.18% upside | $271.17 | Benzinga | Previous targets (3) |
Unknown Wells Fargo | N/A | about 3 years ago | $350 152.25% upside | $270.29 | Benzinga | N/A |
Evan David Seigerman BMO Capital | 0% 0/2 | about 3 years ago | $360 159.45% upside | $197.79 | StreetInsider | Previous targets (1) |
Unknown RBC Capital | N/A | about 3 years ago | $321 131.35% upside | $275.88 | Benzinga | N/A |
Unknown Truist Financial | N/A | about 3 years ago | $265 90.99% upside | $195.92 | Benzinga | N/A |
Unknown Stifel Nicolaus | N/A | about 3 years ago | $223 60.72% upside | $215.38 | Benzinga | N/A |
Unknown Truist Financial | N/A | about 3 years ago | $270 94.59% upside | $213.15 | Benzinga | N/A |
Unknown Needham | N/A | about 3 years ago | $250 80.18% upside | $207.49 | Benzinga | N/A |
Unknown Barclays | N/A | about 3 years ago | $200 44.14% upside | $212.95 | Benzinga | N/A |
Unknown Oppenheimer | N/A | about 3 years ago | $230 65.76% upside | $216.68 | Benzinga | N/A |
Unknown Barclays | N/A | over 3 years ago | $210 51.35% upside | $205.7 | Benzinga | N/A |
Biogen Financial Estimates
Biogen Revenue Estimates
Biogen EBITDA Estimates
Biogen Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $10.98B N/A | $10.17B -7.36% | $9.83B -3.32% | Avg: $9.56B Low: $8.66B High: $10.42B avg. -2.76% | Avg: $9.88B Low: $9.32B High: $10.43B avg. 3.39% | Avg: $10.35B Low: $9.76B High: $10.92B avg. 4.69% | Avg: $10.76B Low: $10.15B High: $11.35B avg. 3.94% |
Net Income
% change YoY
| $1.55B N/A | $3.04B 95.80% | $1.16B -61.89% | Avg: $2.21B Low: $1.39B High: $3.43B avg. 90.93% | Avg: $2.57B Low: $1.80B High: $3.61B avg. 16.20% | Avg: $3.20B Low: $2.97B High: $3.43B avg. 24.51% | Avg: $3.49B Low: $3.23B High: $3.74B avg. 8.99% |
EBITDA
% change YoY
| $3.65B N/A | $2.68B -26.54% | $2.37B -11.50% | Avg: $3.33B Low: $3.01B High: $3.63B avg. 40.15% | Avg: $3.44B Low: $3.24B High: $3.63B avg. 3.39% | Avg: $3.60B Low: $3.40B High: $3.80B avg. 4.69% | Avg: $3.74B Low: $3.53B High: $3.95B avg. 3.94% |
EPS
% change YoY
| $10.44 N/A | $20.97 100.86% | $8.02 -61.75% | Avg: $14.82 Low: $9.6 High: $23.59 avg. 84.83% | Avg: $17.85 Low: $12.42 High: $24.84 avg. 20.38% | Avg: $22.03 Low: $20.41 High: $23.61 avg. 23.46% | Avg: $24.02 Low: $22.24 High: $25.74 avg. 8.99% |
Operating Expenses
% change YoY
| $6.06B N/A | $4.99B -17.65% | $6.00B 20.27% | Avg: $2.08B Low: $1.89B High: $2.27B avg. -65.26% | Avg: $2.15B Low: $2.03B High: $2.27B avg. 3.39% | Avg: $2.25B Low: $2.12B High: $2.38B avg. 4.69% | Avg: $2.34B Low: $2.21B High: $2.47B avg. 3.94% |
FAQ
What is Biogen stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 35.16% in 2025-2028.
We have gathered data from 24 analysts. Their low estimate is 1.39B, average is 2.21B and high is 3.43B.
What is Biogen stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 2.31% in 2025-2028.
We have gathered data from 29 analysts. Their low revenue estimate is $8.66B, average is $9.56B and high is $10.42B.
What is Biogen stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 34.42% in 2025-2028.
We have gathered data from 24 analysts. Their low earnings per share estimate is $9.6, average is $14.82 and high is $23.59.
What is the best performing analyst?
In the last twelve months 8 analysts have been covering Biogen stock. The most successful analyst is Michael Yee whose win rate is 33.33%. He has correctly predicted 1/3 price targets.